Present, emerging and possible future biomarkers in castration resistant prostate cancer (CRPC)

Current Cancer Drug Targets

Volumn 15, Issue 3, 2015, Pages 243-

  Boegemann, Martin ^a   Krabbe, Laura Maria ^a   Herrmann, Edwin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Biomarkers; Castration resistant; MCRPC; Novel therapeutics; Predictive; Prognostic; Surrogate

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DYNAMIN II; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MICRORNA 1290; MICRORNA 17; MICRORNA 221; MICRORNA 23B; MICRORNA 32; MICRORNA 375; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; DOCETAXEL; GENETIC MARKER; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MICRORNA; TAXOID; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; DOWN REGULATION; EXOSOME; HUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE BIOPSY; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; GENETIC MARKER; GENETICS; INFLAMMATION; MALE; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR EMBOLISM;

ALKALINE PHOSPHATASE; BIOMARKERS, TUMOR; GENETIC MARKERS; HUMANS; INFLAMMATION; KALLIKREINS; L-LACTATE DEHYDROGENASE; MALE; MICRORNAS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84929471807     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009615666150204145803     Document Type: Article

References (122)

1. Beer, T.M.; Armstrong, A.J.; Rathkopf, D.E.; Loriot, Y.; Sternberg, C.N.; Higano, C.S.; Iversen, P.; Bhattacharya, S.; Carles, J.; Chowdhury, S.; Davis, I.D.; de Bono, J.S.; Evans, C.P.; Fizazi, K.; Joshua, A.M.; Kim, C.S.; Kimura, G.; Mainwaring, P.; Mansbach, H.; Miller, K.; Noonberg, S.B.; Perabo, F.; Phung, D.; Saad, F.; Scher, H.I.; Taplin, M.E.; Venner, P.M.; Tombal, B.; the PI. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N. Engl. J. Med., 2014. DOI: 10.1056/NEJMoa1405095 [epub ahead of print].
2. Ryan, C.J.; Smith, M.R.; de Bono, J.S.; Molina, A.; Logothetis, C.J.; de Souza, P.; Fizazi, K.; Mainwaring, P.; Piulats, J.M.; Ng, S.; Carles, J.; Mulders, P.F.; Basch, E.; Small, E.J.; Saad, F.; Schrijvers, D.; Van Poppel, H.; Mukherjee, S.D.; Suttmann, H.; Gerritsen, W.R.; Flaig, T.W.; George, D.J.; Yu, E.Y.; Efstathiou, E.; Pantuck, A.; Winquist, E.; Higano, C.S.; Taplin, M.E.; Park, Y.; Kheoh, T.; Griffin, T.; Scher, H.I.; Rathkopf, D.E.; Investigators C-A-. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med., 2013, 368, 138-148.
3. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; Xu, Y.; Frohlich, M.W.; Schellhammer, P.F.; Investigators IS. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 2010, 363, 411-422.
4. de Bono, J.S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, L.; Roessner, M.; Gupta, S.; Sartor, A.O.; Investigators T. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 2010, 376, 1147-1154.
5. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; Lara, P.N. Jr.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M.C.; Small, E.J.; Raghavan, D.; Crawford, E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med., 2004, 351, 1513-1520.
6. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Theodore, C.; James, N.D.; Turesson, I.; Rosenthal, M.A.; Eisenberger, M.A.; Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004, 351, 1502-1512.
7. Scher, H.I.; Fizazi, K.; Saad, F.; Taplin, M.E.; Sternberg, C.N.; Miller, K.; de Wit, R.; Mulders, P.; Chi, K.N.; Shore, N.D.; Armstrong, A.J.; Flaig, T.W.; Flechon, A.; Mainwaring, P.; Fleming, M.; Hainsworth, J.D.; Hirmand, M.; Selby, B.; Seely, L.; de Bono, J.S.; Investigators A. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 2012, 367, 1187-1197.
8. de Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B. Jr.; Saad, F.; Staffurth, J.N.; Mainwaring, P.; Harland, S.; Flaig, T.W.; Hutson, T.E.; Cheng, T.; Patterson, H.; Hainsworth, J.D.; Ryan, C.J.; Sternberg, C.N.; Ellard, S.L.; Flechon, A.; Saleh, M.; Scholz, M.; Efstathiou, E.; Zivi, A.; Bianchini, D.; Loriot, Y.; Chieffo, N.; Kheoh, T.; Haqq, C.M.; Scher, H.I.; Investigators C-A-. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med., 2011, 364, 1995-2005.
9. Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S.I.; O'Sullivan, J.M.; Fossa, S.D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; Widmark, A.; Johannessen, D.C.; Hoskin, P.; Bottomley, D.; James, N.D.; Solberg, A.; Syndikus, I.; Kliment, J.; Wedel, S.; Boehmer, S.; Dall'Oglio, M.; Franzen, L.; Coleman, R.; Vogelzang, N.J.; O'Bryan-Tear, C.G.; Staudacher, K.; Garcia-Vargas, J.; Shan, M.; Bruland, O.S.; Sartor, O.; Investigators A. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med., 2013, 369, 213-223.
10. Pili, R.; Haggman, M.; Stadler, W.M.; Gingrich, J.R.; Assikis, V.J.; Bjork, A.; Nordle, O.; Forsberg, G.; Carducci, M.A.; Armstrong, A.J. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J. Clin. Oncol., 2011, 29, 4022-4028.
11. Montgomery, R.B.; Eisenberger, M.A.; Rettig M.; Chu, F.; Pili, R.; Stephenson, J.; Vogelzang, N.J.; Morrison, J.; Taplin, M.-E. Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). J. Clin. Oncol., 2012, 30, 4665.
12. Sweeney, C.; Chen, Y.; Carducci, M.A.; Liu, G.; Jarrard, D.F; Eisenberger, M.A.; Wong, Y.-N.; Hahn, N.; Kohli, M.; Vogelzang, N.J.; Cooney, M.; Dreicer, R.; Picus, J.; Shevrin, D.; Hussain, M.; Garcia, J.; DiPaola, R. Impact on overall survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer: An ECOG-led phase III randomized trial. J. Clin. Oncol., 2014, 32, 5s: asbtr LBA2.
13. Ryan, C.J.; Shah, S.; Efstathiou, E.; Smith, M.R.; Taplin, M.E.; Bubley, G.J.; Logothetis, C.J.; Kheoh, T.; Kilian, C.; Haqq, C.M.; Molina, A.; Small, E.J. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res., 2011, 17, 4854-4861.
14. Strimbu, K.; Tavel, J.A. What are biomarkers? Curr. Opin. HIV AIDS, 2010, 5, 463-466.
15. Safety WIPoC. Biomarkers and Risk Assessment: Concepts and Principles. Retrieves from: http://wwwinchemorg/documents/ehc/ ehc/ehc155htm. 1993.
16. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69, 89-95.
17. Schroder, F.H.; Hugosson, J.; Roobol, M.J.; Tammela, T.L.; Zappa, M.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Maattanen, L.; Lilja, H.; Denis, L.J.; Recker, F.; Paez, A.; Bangma, C.H.; Carlsson, S.; Puliti, D.; Villers, A.; Rebillard, X.; Hakama, M.; Stenman, U.H.; Kujala, P.; Taari, K.; Aus, G.; Huber, A.; van der Kwast, T.H.; van Schaik, R.H.; de Koning, H.J.; Moss, S.M.; Auvinen, A.; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, 2014, DOI: 10.1016/S0140-6736(14)60525-0 [e-pub ahead of print].
18. Andriole, G.L.; Crawford, E.D.; Grubb, R.L.; Buys, S.S.; Chia, D.; Church, T.R.; Fouad, M.N.; Isaacs, C.; Kvale, P.A.; Reding, D.J.; Weissfeld, J.L.; Yokochi, L.A.; O'Brien, B.; Ragard, L.R.; Clapp, J.D.; Rathmell, J.M.; Riley, T.L.; Hsing, A.W.; Izmirlian, G.; Pinsky, P.F.; Kramer, B.S.; Miller, A.B.; Gohagan, J.K.; Prorok, P.C.; Team, P.P. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up. J. Natl. Cancer Inst., 2012, 104, 125-132.
19. Vickers, A.J.; Savage, C.; O'Brien, M.F.; Lilja, H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol., 2009, 27, 398-403.
20. Vickers, A.J.; Brewster, S.F. PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br. J. Med. Surg. Urol., 2012, 5, 162-168.
21. Pound, C.R.; Partin, A.W.; Eisenberger, M.A.; Chan, D.W.; Pearson, J.D.; Walsh, P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 1999, 281, 1591-1597.
22. D'Amico, A.V.; Cote, K.; Loffredo, M.; Renshaw, A.A.; Schultz, D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J. Clin. Oncol., 2002, 20, 4567-4573.
23. Vollmer, R.T.; Dawson, N.A.; Vogelzang, N.J. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer, 1998, 83, 1989-1994.
24. Armstrong, A.J.; Garrett-Mayer, E.S.; Yang, Y.C.; de Wit, R.; Tannock, I.F.; Eisenberger, M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res., 2007, 13, 6396-6403.
25. Halabi, S.; Small, E.J.; Kantoff, P.W.; Kattan, M.W.; Kaplan, E.B.; Dawson, N.A.; Levine, E.G.; Blumenstein, B.A.; Vogelzang, N.J. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol., 2003, 21, 1232-1237.
26. Daskivich, T.J.; Regan, M.M.; Oh, W.K. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology, 2007, 70, 527-531.
27. Oudard, S.; Banu, E.; Scotte, F.; Banu, A.; Medioni, J.; Beuzeboc, P.; Joly, F.; Ferrero, J.M.; Goldwasser, F.; Andrieu, J.M. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann. Oncol., 2007, 18, 1828-1833.
28. Scher, H.I.; Morris, M.J.; Basch, E.; Heller, G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J. Clin. Oncol., 2011, 29, 3695-3704.
29. Petrylak, D.P.; Ankerst, D.P.; Jiang, C.S.; Tangen, C.M.; Hussain, M.H.; Lara, P.N.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Kohli, M.; Benson, M.C.; Small, E.J.; Raghavan, D.; Crawford, E.D. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst., 2006, 98, 516-521.
30. Darshan, M.S.; Loftus, M.S.; Thadani-Mulero, M.; Levy, B.P.; Escuin, D.; Zhou, X.K.; Gjyrezi, A.; Chanel-Vos, C.; Shen, R.; Tagawa, S.T.; Bander, N.H.; Nanus, D.M.; Giannakakou, P. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res., 2011, 71, 6019-6029.
31. Berthold, D.R.; Pond, G.R.; Roessner, M.; de Wit, R.; Eisenberger, M.; Tannock, A.I.; Investigators TAX. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin. Cancer Res., 2008, 14, 2763-2767.
32. de Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C.; Miller, M.C.; Tissing, H.; Doyle, G.V.; Terstappen, L.W.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin, Cancer Res., 2008, 14, 6302-6309.
33. Flechon, A.; Pouessel, D.; Ferlay, C.; Perol, D.; Beuzeboc, P.; Gravis, G.; Joly, F.; Oudard, S.; Deplanque, G.; Zanetta, S.; Fargeot, P.; Priou, F.; Droz, J.P.; Culine, S. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann. Oncol., 2011, 22, 2476-2481.
34. Catalona, W.J.; Smith, D.S.; Wolfert, R.L.; Wang, T.J.; Rittenhouse, H.G.; Ratliff, T.L.; Nadler, R.B. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 1995, 274, 1214-1220.
35. Lazzeri, M.; Briganti, A.; Scattoni, V.; Lughezzani, G.; Larcher, A.; Gadda, G.M.; Lista, G.; Cestari, A.; Buffi, N.; Bini, V.; Freschi, M.; Rigatti, P.; Montorsi, F.; Guazzoni, G. Serum index test % [-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J. Urol., 2012, 188, 1137-1143.
36. Mikolajczyk, S.D.; Millar, L.S.; Wang, T.J.; Rittenhouse, H.G.; Marks, L.S.; Song, W.; Wheeler, T.M.; Slawin, K.M. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res., 2000, 60, 756-759.
37. Mikolajczyk, S.D.; Marker, K.M.; Millar, L.S.; Kumar, A.; Saedi, MS.; Payne, J.K.; Evans, C.L.; Gasior, C.L.; Linton, H.J.; Carpenter, P.; Rittenhouse, H.G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res., 2001, 61, 6958-6963.
38. Lazzeri, M.; Haese, A.; Abrate, A.; de la Taille, A.; Redorta, J.P.; McNicholas, T.; Lughezzani, G.; Lista, G.; Larcher, A.; Bini, V.; Cestari, A.; Buffi, N.; Graefen, M.; Bosset, O.; Le Corvoisier, P.; Breda, A.; de la Torre, P.; Fowler, L.; Roux, J.; Guazzoni, G. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int., 2013, 112, 313-321.
39. Le, B.V.; Griffin, C.R.; Loeb, S.; Carvalhal, G.F.; Kan, D.; Baumann, N.A.; Catalona, W.J. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J. Urol., 2010, 183, 1355-1359.
40. Sokoll, L.J.; Sanda, M.G.; Feng, Z.; Kagan, J.; Mizrahi, I.A.; Broyles, D.L.; Partin, A.W.; Srivastava, S.; Thompson, I.M.; Wei, J.T.; Zhang, Z.; Chan, D.W. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 1193-1200.
41. Catalona, W.J.; Bartsch, G.; Rittenhouse, H.G.; Evans, C.L.; Linton, H.J.; Amirkhan, A.; Horninger, W.; Klocker, H.; Mikolajczyk, S.D. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J. Urol., 2003, 170, 2181-2185.
42. Guazzoni, G.; Nava, L.; Lazzeri, M.; Scattoni, V.; Lughezzani, G.; Maccagnano, C.; Dorigatti, F.; Ceriotti, F.; Pontillo, M.; Bini, V.; Freschi, M.; Montorsi, F.; Rigatti, P. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur. Urol., 2011, 60, 214-222.
43. Filella, X.; Gimenez, N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin. Chem. Lab Med., 2013, 51, 729-739.
44. Berry, W.R.; Laszlo, J.; Cox, E.; Walker, A.; Paulson, D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer, 1979, 44, 763-775.
45. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J. Clin. Oncol., 1997, 15, 594-603.
46. Nilsson, S.; Franzen, L.; Parker, C.; Tyrrell, C.; Blom, R.; Tennvall, J.; Lennernas, B.; Petersson, U.; Johannessen, D.C.; Sokal, M.; Pigott, K.; Yachnin, J.; Garkavij, M.; Strang, P.; Harmenberg, J.; Bolstad, B.; Bruland, O.S. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol., 2007, 8, 587-594.
47. Sonpavde, G.; Pond, G.R.; Berry, W.R.; de Wit, R.; Armstrong, A.J.; Eisenberger, M.A.; Tannock, I.F. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol. Oncol., 2012, 30, 607-613.
48. Matsuyama, H.; Shimabukuro, T.; Hara, I.; Kohjimoto, Y.; Suzuki, K.; Koike, H.; Uemura, H.; Hayashi, T.; Ueno, M.; Kodaira, K.; Tomita, Y.; Sakurai, T.; Shimizu, N. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int. J. Clin. Oncol., 2013.
49. Han, K.S.; Hong, S.J. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with one metastasis. J. Cancer Res. Clin. Oncol., 2014, 140, 1769-1776.
50. Brat, D.J.; Bellail, A.C.; Van Meir, E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol., 2005, 7, 122-133.
51. Sharma, J.; Gray, K.P.; Harshman, L.C.; Evan, C.; Nakabayashi, M.; Fichorova, R.; Rider, J.; Mucci, L.; Kantoff, P.W.; Sweeney, C.J. Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate, 2014, 74, 820-828.
52. Lu, H.; Ouyang, W.; Huang, C. Inflammation, a key event in cancer development. Mol. Cancer Res., 2006, 4, 221-233.
53. Ito, M.; Saito, K.; Yasuda, Y.; Sukegawa, G.; Kubo, Y.; Numao, N.; Kitsukawa, S.; Urakami, S.; Yuasa, T.; Yamamoto, S.; Yonese, J.; Fukui, I. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology. 2011, 78, 1131-1135.
54. Prins, R.C.; Rademacher, B.L.; Mongoue-Tchokote, S.; Alumkal, J.J.; Graff, J.N.; Eilers, K.M.; Beer, T.M. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol. Oncol., 2012, 30, 33-37.
55. Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X.W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R.; Lee, C.; Montie, J.E.; Shah, R.B.; Pienta, K.J.; Rubin, M.A.; Chinnaiyan, A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 2005, 310, 644-648.
56. Laxman, B.; Tomlins, S.A.; Mehra, R.; Morris, D.S.; Wang, L.; Helgeson, B.E.; Shah, R.B.; Rubin, M.A.; Wei, J.T.; Chinnaiyan, A.M. Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia, 2006, 8, 885-888.
57. Magi-Galluzzi, C.; Tsusuki, T.; Elson, P.; Simmerman, K.; LaFargue, C.; Esgueva, R.; Klein, E.; Rubin, M.A.; Zhou, M. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate, 2011, 71, 489-497.
58. Pettersson, A.; Graff, R.E.; Bauer, S.R.; Pitt, M.J.; Lis, R.T.; Stack, E.C.; Martin, N.E.; Kunz, L.; Penney, K.L.; Ligon, A.H.; Suppan, C.; Flavin, R.; Sesso, H.D.; Rider, J.R.; Sweeney, C.; Stampfer, M.J.; Fiorentino, M.; Kantoff, P.W.; Sanda, M.G.; Giovannucci, E.L.; Ding, E.L.; Loda, M.; Mucci, L.A. The TMPRSS2: ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol. Biomarkers Prev., 2012, 21, 1497-1509.
59. Hessels, D.; Smit, F.P.; Verhaegh, G.W.; Witjes, J.A.; Cornel, E.B.; Schalken, J.A. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res., 2007, 13, 5103-5108.
60. Danila, D.C.; Anand, A.; Sung, C.C.; Heller, G.; Leversha, M.A.; Cao, L.; Lilja, H.; Molina, A.; Sawyers, C.L.; Fleisher, M.; Scher, H.I. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol., 2011, 60, 897-904.
61. Dijkstra, S.; Leyten, G.H.; Jannink, S.A.; de Jong, H.; Mulders, P.F.; van Oort, I.M.; Schalken, J.A. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. Prostate, 2014, 74, 1222-1230.
62. Taris, M.; Irani, J.; Blanchet, P.; Multigner, L.; Cathelineau, X.; Fromont, G. ERG expression in prostate cancer: The prognostic paradox. Prostate, 2014, 74, 1481-1487.
63. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem., 2010, 56, 1733-1741.
64. Bryant, R.J.; Pawlowski, T.; Catto, J.W.; Marsden, G.; Vessella, R.L.; Rhees, B.; Kuslich, C.; Visakorpi, T.; Hamdy, F.C. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer, 2012, 106, 768-774.
65. Kuner, R.; Brase, J.C.; Sultmann, H.; Wuttig, D. microRNA biomarkers in body fluids of prostate cancer patients. Methods, 2013, 59, 132-137.
66. Sun, T.; Yang, M.; Chen, S.; Balk, S.; Pomerantz, M.; Hsieh, C.L.; Brown, M.; Lee, G.S.; Kantoff, P.W. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate, 2012, 72, 1093-1103.
67. Sun, T.; Wang, X.; He, H.H.; Sweeney, C.J.; Liu, S.X.; Brown, M.; Balk, S.; Lee, G.S.; Kantoff, P.W. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene, 2014, 33, 2790-800.
68. Jalava, S.E.; Urbanucci, A.; Latonen, L.; Walteringm, K.K.; Sahu, B.; Janne, O.A.; Seppala, J.; Lahdesmaki, H.; Tammela, T.L.; Visakorpi, T. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene, 2012, 31, 4460-4471.
69. Lin, H.M.; Castillo, L.; Mahon, K.L.; Chiam, K.; Lee, B.Y.; Nguyen, Q.; Boyer, M.J.; Stockler, M.R.; Pavlakis, N.; Marx, G.; Mallesara, G.; Gurney, H.; Clark, S.J.; Swarbrick, A.; Daly, R.J.; Horvath, L.G. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br. J. Cancer, 2014, 110, 2462-2471.
70. Sapre, N.; Selth, L.A. Circulating MicroRNAs as biomarkers of prostate cancer: The state of play. Prostate Cancer, 2013, 2013, 539680.
71. Thery, C.; Zitvogel, L.; Amigorena, S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol., 2002, 2, 569-579.
72. Miranda, K.C.; Bond, D.T.; McKee, M.; Skog, J.; Paunescu, T.G.; Da Silva, N.; Brown, D.; Russo, L.M. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int., 2010, 78, 191-199.
73. Nilsson, J.; Skog, J.; Nordstrand, A.; Baranov, V.; Mincheva-Nilsson, L.; Breakefield, X.O.; Widmark, A. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer, 2009, 100, 1603-1607.
74. Mitchell, P.J.; Welton, J.; Staffurth, J.; Court, J.; Mason, M.D.; Tabi, Z.; Clayton, A. Can urinary exosomes act as treatment response markers in prostate cancer? J. Transl. Med., 2009, 7, 4.
75. Huang, X.; Yuan, T.; Liang, M.; Du, M.; Xia, S.; Dittmar, R.; Wang, D.; See, W.; Costello, B.A.; Quevedo, F.; Tan, W.; Nandy, D.; Bevan, G.H.; Longenbach, S.; Sun, Z.; Lu, Y.; Wang, T.; Thibodeau, S.N; Broadman, L.; ; Kohli, M. ; Wang, L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur. Urol., 2014.
76. Olmos, D.; Arkenau, H.T.; Ang, J.E.; Ledaki, I.; Attard, G.; Carden, C.P.; Reid, A.H.; A'Hern, R.; Fong, P.C.; Oomen, N.B.; Molife, R.; Dearnaley, D.; Parker, C.; Terstappen, L.W.; de Bono, J.S. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann. Oncol., 2009, 20, 27-33.
77. Scher, H.I.; Jia, X.; de Bono, J.S.; Fleisher, M.; Pienta, K.J.; Raghavan, D.; Heller, G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol., 2009, 10, 233-239.
78. Scher, H.I.; Heller, G.; Molina, A. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COA-AA-301, a rondomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J. Clin. Oncol., 2011, 29, LBA4517.
79. Scher, H.I.; Morris, M.J.; Larson, S.; Heller, G. Validation and clinical utility of prostate cancer biomarkers. Nat. Rev. Clin. Oncol., 2013, 10, 225-234.
80. Danila, D.C.; Anand, A.; Schultz, N.; Heller, G.; Wan, M.; Sung, C.C.; Dai, C.; Khanin, R.; Fleisher, M.; Lilja, H.; Scher, H.I. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur. Urol., 2014, 65, 1191-1197.
81. Antonarakis, E.S.; Lu, C.; Wang, H.; Luber, B.; Nakazawa, M.; Roeser, J.C.; Chen, Y.; Mohammad, T.A.; Chen, Y.; Fedor, H.L.; Lotan, T.L.; Zheng, Q.; De Marzo, A.M.; Isaacs, J.T.; Isaacs, W.B.; Nadal, R.; Paller, C.J.; Denmeade, S.R.; Carducci, M.A.; Eisenberger, M.A.; Luo, J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med., 2014, 371, 1028-1038.
82. Schrader, A.J.; Boegemann, M.; Ohlmann, C.H.; Schnoeller, T.J.; Krabbe, L.M.; Hajili, T.; Jentzmik, F.; Stoeckle, M.; Schrader, M.; Herrmann, E.; Cronauer, M.V. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur. Urol., 2014, 65, 30-36.
83. Brasso, K.; Thomsen, F.B.; Schrader, A.J.; Schmid, S.C.; Lorente, D.; Retz, M.; Merseburger, A.S.; von Klot, C.A.; Boegemann, M.; de Bono, J. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: A multicentre analysis. Eur. Urol., 2014.
84. Loriot, Y.; Bianchini, D.; Ileana, E.; Sandhu, S.; Patrikidou, A.; Pezaro, C.; Albiges, L.; Attard, G.; Fizazi, K.; De Bono, J.S.; Massard, C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann. Oncol., 2013, 24, 1807-1812.
85. Noonan, K.L.; North, S.; Bitting, R.L.; Armstrong, A.J.; Ellard, S.L.; Chi, K.N. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann. Oncol., 2013, 24, 1802-1807.
86. Thadani-Mulero, M.; Portella, L.; Sun, S.; Sung, M.; Matov, A.; Vessella, R.L.; Corey, E.; Nanus, D.M.; Plymate, S.R.; Giannakakou, P. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res., 2014, 74, 2270-2282.
87. Cao, Q.; Yu, J.; Dhanasekaran, S.M.; Kim, J.H.; Mani, R.S.; Tomlins, S.A.; Mehra, R.; Laxman, B.; Cao, X.; Yu, J.; Kleer, C.G.; Varambally, S.; Chinnaiyan, A.M. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 2008, 27, 7274-7284.
88. Chaux, A.; Peskoe, S.B.; Gonzalez-Roibon, N.; Schultz, L.; Albadine, R.; Hicks, J.; De Marzo, A.M.; Platz, E.A.; Netto, G.J. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod. Pathol., 2012, 25, 1543-1549.
89. Khatami, A.; Hugosson, J.; Wang, W.; Damber, J.E. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Scand. J. Urol. Nephrol., 2009, 43, 12-18.
90. Umbas, R.; Isaacs, W.B.; Bringuier, P.P.; Xue, Y.; Debruyne, F.M.; Schalken, J.A. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int. J. Cancer, 1997, 74, 374-377.
91. Cooperberg, M.R.; Simko, J.P.; Cowan, J.E.; Reid, J.E.; Djalilvand, A.; Bhatnagar, S.; Gutin, A.; Lanchbury, J.S.; Swanson, G.P.; Stone, S.; Carroll, P.R. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J. Clin. Oncol., 2013, 31, 1428-1434.
92. Cuzick, J.; Swanson, G.P.; Fisher, G.; Brothman, A.R.; Berney, D.M.; Reid, J.E.; Mesher, D.; Speights, V.O.; Stankiewicz, E.; Foster, C.S.; Moller, H.; Scardino, P.; Warren, J.D.; Park, J.; Younus, A.; Flake, D.D.; Wagner, S.; Gutin, A.; Lanchbury, J.S.; Stone, S.; Transatlantic Prostate G. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol., 2011, 12, 245-255.
93. Xu, B.; Teng, L.H.; Silva, S.D.; Bijian, K.; Al Bashir, S.; Jie, S.; Dolph, M.; Alaoui-Jamali, M.A.; Bismar, T.A. The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. Cancer Med., 2014, 3, 14-24.
94. Chemnitz, J.M.; Parry, R.V.; Nichols, K.E.; June, C.H.; Riley, J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol., 2004, 173, 945-954.
95. Topalian, S.L.; Sznol, M.; McDermott, D.F.; Kluger, H.M.; Carvajal, R.D.; Sharfman, W.H.; Brahmer, J.R.; Lawrence, D.P.; Atkins, M.B.; Powderly, J.D.; Leming, P.D.; Lipson, E.J.; Puzanov, I.; Smith, D.C.; Taube, J.M.; Wigginton, J.M.; Kollia, G.D.; Gupta, A.; Pardoll, D.M.; Sosman, J.A.; Hodi, F.S. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol., 2014, 32, 1020-1030.
96. Bishop, J.L.; Sio, A.; Angeles, A.; Roberts ME.; Azad AA.; Chi KN.; Zoubeidi A. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget, 2014.
97. Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res., 2014, 20, 5064-5074.
98. Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; Bramley, A.H.; Vincent, L.; Costa, C.; MacDonald, D.D.; Jin, D.K.; Shido, K.; Kerns, S.A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J.L.; Altorki, N.; Port, E.R.; Ruggero, D.; Shmelkov, S.V.; Jensen, K.K.; Rafii, S.; Lyden, D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 2005, 438, 820-827.
99. Gangemi, R.; Paleari, L.; Orengo, A.M.; Cesario, A.; Chessa, L.; Ferrini, S.; Russo, P. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr. Med. Chem., 2009, 16, 1688-1703.
100. Mraz, M.; Zent, C.S.; Church, A.K.; Jelinek, D.F.; Wu, X.; Pospisilova, S.; Ansell, S.M.; Novak, A.J.; Kay, N.E.; Witzig, T.E.; Nowakowski, G.S. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br. J. Haematol., 2011, 155, 53-64.
101. Ni, J.; Cozzi, P.; Hao, J.; Duan, W.; Graham, P.; Kearsley, J.; Li, Y. Cancer stem cells in prostate cancer chemoresistance. Curr. Cancer Drug Targets, 2014, 14, 225-240.
102. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res., 2005, 65, 10946-10951.
103. Espinoza, I.; Pochampally, R.; Xing, F.; Watabe, K.; Miele, L. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco. Targets Ther., 2013, 6, 1249-1259.
104. Ranganathan, P.; Weaver, K.L.; Capobianco, A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer, 2011, 11, 338-351.
105. Hutchin, M.E.; Kariapper, M.S.; Grachtchouk, M.; Wang, A.; Wei, L.; Cummings, D.; Liu, J.; Michael, L.E.; Glick, A.; Dlugosz, A.A. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev., 2005, 19, 214-223.
106. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111.
107. Vidal, S.J.; Rodriguez-Bravo, V.; Galsky, M.; Cordon-Cardo, C.; Domingo-Domenech, J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene, 2014, 33, 4451-4463.
108. Archive HGP. About the Human Genome Project. http://webornlgov/sci/techresources/Human_Genome/project/indexshtml.
109. genome.com.http://www.genome.gov/sequencingcosts/.
110. Lin, P.C.; Giannopoulou, E.G.; Park, K.; Mosquera, J.M.; Sboner, A.; Tewari, A.K.; Garraway, L.A.; Beltran, H.; Rubin, M.A.; Elemento, O. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia, 2013, 15, 373-383.
111. Heitzer, E.; Ulz, P.; Belic, J.; Gutschi, S.; Quehenberger, F.; Fischereder, K.; Benezeder, T.; Auer, M.; Pischler, C.; Mannweiler, S.; Pichler, M.; Eisner, F.; Haeusler, M.; Riethdorf, S.; Pantel, K.; Samonigg, H.; Hoefler, G.; Augustin, H.; Geigl, J.B.; Speicher, M.R. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med., 2013, 5, 30.
112. Menon, R.; Deng, M.; Ruenauver, K.; Queisser, A.; Peifer, M.; Offermann, A.; Boehm, D.; Vogel, W.; Scheble, V.; Fend, F.; Kristiansen, G.; Wernert, N.; Oberbeckmann, N.; Biskup, S.; Rubin, M.A.; Shaikhibrahim, Z.; Perner, S. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer. J. Pathol., 2013, 231, 505-516.
113. Sowalsky, A.G.; Xia, Z.; Wang, L.; Zhao, H.; Chen, S.; Bubley, G.J.; Balk, S.P.; Li, W. Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol. Cancer Res., 2014.
114. Osborne, J.R.; Akhtar, N.H.; Vallabhajosula, S.; Anand, A.; Deh, K.; Tagawa, S.T. Prostate-specific membrane antigen-based imaging. Urol. Oncol., 2013, 31, 144-154.
115. Evans, M.J.; Smith-Jones, P.M.; Wongvipat, J.; Navarro, V.; Kim, S.; Bander, N.H.; Larson, S.M.; Sawyers, C.L. Noninvasive measurement of androgen receptor signaling with a positron- emitting radio- pharmaceutical that targets prostate-specific membrane antigen. Proc. Natl. Acad. Sci. U.S.A., 2011, 108, 9578-9582.
116. Erdi, Y.E.; Humm, J.L.; Imbriaco, M.; Yeung, H.; Larson, S.M. Quantitative bone metastases analysis based on image segmentation. J. Nucl. Med., 1997, 38, 1401-1406.
117. Sabbatini, P.; Larson, S.M.; Kremer, A.; Zhang, Z.F.; Sun, M.; Yeung, H.; Imbriaco, M.; Horak, I.; Conolly, M.; Ding, C.; Ouyang, P.; Kelly, W.K.; Scher, H.I. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J. Clin. Oncol., 1999, 17, 948-957.
118. Kaboteh, R.; Gjertsson, P.; Leek, H.; Lomsky, M.; Ohlsson, M.; Sjostrand, K.; Edenbrandt, L. Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Res., 2013, 3, 64.
119. Ulmert, D.; Kaboteh, R.; Fox, J.J.; Savage, C.; Evans, M.J.; Lilja, H.; Abrahamsson, P.A.; Bjork, T.; Gerdtsson, A.; Bjartell, A.; Gjertsson, P.; Hoglund, P.; Lomsky, M.; Ohlsson, M.; Richter, J.; Sadik, M.; Morris, M.J.; Scher, H.I.; Sjostrand, K.; Yu, A.; Suurkula, M.; Edenbrandt, L.; Larson, S.M. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur. Urol., 2012, 62, 78-84.
120. Mitsui, Y.; Shiina, H.; Yamamoto, Y.; Haramoto, M.; Arichi, N.; Yasumoto, H.; Kitagaki, H.; Igawa, M. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int., 2012, 110, E628-34.
121. De Wit, R.; Fizazi, K.; Jinga, V.; Efstathiou, E.; Fong, P.C.; Wirth, M.; Suzuki, K.; Moran, S.; Wang, L.; Akaza, H.; Nelson, J.; Scher, H.I.; Dreicer, R.; Borgstein, N.; Saad, F. Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. J. Clin. Oncol., 2014, 32, 5s: abstract 5008.
122. Smith, D.C.; Smith, M.R.; Sweeney, C.; Elfiky, A.A.; Logothetis, C.; Corn, P.G.; Vogelzang, N.J.; Small, E.J.; Harzstark, A.L.; Gordon, M.S.; Vaishampayan, U.N.; Haas, N.B.; Spira, A.I.; Lara, P.N.; Lin, C.C.; Srinivas, S.; Sella, A.; Schoffski, P.; Scheffold, C.; Weitzman, A.L.; Hussain, M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol., 2013, 31, 412-419.